Page last updated: 2024-10-24

negative regulation of lipoprotein lipase activity

Definition

Target type: biologicalprocess

Any process that stops or reduces the activity of the enzyme lipoprotein lipase. [GOC:ai]

Negative regulation of lipoprotein lipase (LPL) activity is a complex process that ensures the efficient and controlled hydrolysis of triglycerides within lipoproteins, particularly those circulating in the bloodstream. This process is tightly regulated, ensuring proper lipid metabolism and preventing the accumulation of excess lipids in tissues.

**Key Players and Mechanisms**

* **LPL itself:** LPL is an enzyme bound to the surface of capillary endothelial cells, where it breaks down triglycerides in lipoproteins (primarily chylomicrons and very low-density lipoproteins (VLDL)) into fatty acids and glycerol. This process is essential for the delivery of fatty acids to peripheral tissues for energy and biosynthesis.

* **Hormonal regulation:** Several hormones influence LPL activity:
* **Insulin:** Stimulates LPL activity, enhancing triglyceride hydrolysis and promoting fatty acid uptake by tissues.
* **Glucagon:** Inhibits LPL activity, reducing triglyceride hydrolysis and favoring fat storage.
* **Epinephrine:** Also inhibits LPL activity, promoting lipolysis (fat breakdown) in adipose tissue and increasing free fatty acids in the bloodstream.

* **Other regulatory factors:**
* **Apolipoproteins:** These proteins associated with lipoproteins interact with LPL, influencing its activity. For instance, ApoCII enhances LPL activity, while ApoCIII inhibits it.
* **Lipoprotein lipase inhibitors:** These include angiopoietin-like protein 4 (ANGPTL4) and glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1). ANGPTL4 inhibits LPL activity in the blood and adipose tissue, while GPIHBP1 enhances LPL activity by mediating its binding to the endothelial surface.

**Mechanisms of Negative Regulation:**

* **Inhibition of LPL activity:**
* **Hormonal control:** Glucagon and epinephrine, as mentioned earlier, directly inhibit LPL activity.
* **Specific inhibitors:** ANGPTL4 plays a key role in negative regulation by directly inhibiting LPL activity.
* **ApoCIII:** This apolipoprotein competes with ApoCII for binding to LPL, ultimately inhibiting its activity.

* **Reduced LPL expression:**
* **Hormonal signals:** Glucagon and epinephrine can decrease LPL expression at the gene level, reducing the overall amount of LPL available.
* **Nutritional factors:** A high-fat diet has been shown to suppress LPL expression.

* **Alteration of LPL localization:**
* **Increased LPL clearance:** Factors like inflammation and elevated levels of certain cytokines can trigger increased clearance of LPL from the endothelial surface, reducing its activity.

**Physiological Significance**

* **Metabolic control:** Negative regulation of LPL activity ensures that triglycerides are not broken down prematurely, allowing for their delivery to specific tissues as needed.
* **Lipid homeostasis:** This regulation helps maintain balanced lipid levels in the bloodstream, preventing the accumulation of excess triglycerides and cholesterol.
* **Tissue-specific delivery:** It allows for the selective delivery of fatty acids to different tissues based on their specific metabolic requirements.

**Disruptions and Implications**

* **Hypertriglyceridemia:** Dysregulation of LPL activity can contribute to hypertriglyceridemia, a condition characterized by elevated triglyceride levels in the blood, increasing the risk of cardiovascular disease.
* **Metabolic disorders:** Mutations in genes involved in LPL regulation can lead to genetic disorders, including familial LPL deficiency, characterized by severe hypertriglyceridemia and pancreatitis.

**In summary, negative regulation of LPL activity is a crucial process that ensures efficient and controlled lipid metabolism, maintaining proper lipid homeostasis and preventing the buildup of excess lipids in the bloodstream. Understanding this process is essential for developing strategies to manage lipid disorders and improve cardiovascular health.**'
"

Proteins (1)

ProteinDefinitionTaxonomy
SortilinA sortilin that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q99523]Homo sapiens (human)

Compounds (3)

CompoundDefinitionClassesRoles
sr 48692SR 48692: structure in first source; a neurotensin receptor-1 antagonistN-acyl-amino acid
neurotensinneurotensin, Tyr(11)-: RN given refers to parent cpd & (D)-isomer; RN for cpd without isomeric designation not avail 5/91peptide hormonehuman metabolite;
mitogen;
neurotransmitter;
vulnerary
af38469